{
    "clinical_study": {
        "@rank": "119385", 
        "acronym": "BCPP", 
        "arm_group": [
            {
                "arm_group_label": "Combination Prevention", 
                "arm_group_type": "Experimental", 
                "description": "Rapid scale-up of HTC services during two annual HTC campaigns, with a target of ensuring >90% of adults aged 16-64 have documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.\nRapid scale-up of ART for adults with CD4\u2264350 cells/\u00b5L, or WHO Stage III/IV, with a target of ensuring that >90% of these ART-eligible adults are receiving ART.\nRapid scale-up of ART for adults with a viral load \u226510,000 copies/ml, CD4>350, and WHO Stage I/II with a target of ensuring that >80% of these ART-eligible adults are receiving ART.\nRapid scale-up of male circumcision service uptake, with a target of ensuring >80% of HIV-negative men (aged 16-49) are circumcised.\nRapid scale-up of PMTCT services, with a target of ensuring >90% of pregnant women with HIV receive recommended PMTCT antiretrovirals before 28 weeks gestation, and >90% continue ART indefinitely after starting ART for PMTCT if otherwise ineligible for treatment."
            }, 
            {
                "arm_group_label": "Enhanced Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Enhanced Care Communities will receive enhancements and improved support for clinical and laboratory data information systems and supply chain management at all local clinics at which individuals receive HIV care and treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "The BCPP study is designed to test the hypothesis that implementing an enhanced combination\n      prevention package which includes provision of ART as prevention for HIV-infected\n      individuals with HIV-1 RNA \u226510,000 copies/ml will impact the HIV/AIDS epidemic by\n      significantly reducing population-level, cumulative HIV incidence in a defined geographic\n      area over a period of 3 years and will be cost-effective."
        }, 
        "brief_title": "Botswana Combination Prevention Project", 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Protocol #1 - Baseline Household Survey (BHS):  Permanent or part-time study\n             community resident in any of the 30 study communities; Botswana citizen or spouse of\n             a Botswana citizen; able to provide informed consent if \u226518 years old, or able to\n             provide assent to complement a guardian's permission, if a minor (aged 16 or 17).\n\n          -  Protocol #2 - Closed clinical cohort:  Eligible household members identified during\n             the initial year BHS who are permanent study community residents, intend to be\n             permanent study community residents for the next 12 months, with HIV-1 infection, CD4\n             >350 cells/\u00b5L and WHO State I/II, ART na\u00efve, and able to provide informed consent if\n             \u226518 years old, or able to provide assent to complement a guardian's permission, if a\n             minor (aged 16 or 17).\n\n          -  Protocol #3 - Expanded treatment cohort:  HIV-infected persons in Combination\n             Prevention communities identified after the initial BHS who are not yet on ART, have\n             CD4>350 cells/\u00b5L and WHO Stage I/II, and 1) have HIV-1 RNA>10,0000 copies/mL or 2)\n             are pregnant, and are able to provide informed consent if \u226518 years old, or able to\n             provide assent to complement a guardian's permission, if a minor (aged 16 or 17).\n\n        Exclusion Criteria:\n\n          -  Persons who do not meet inclusion criteria."
            }, 
            "gender": "Both", 
            "maximum_age": "64 Years", 
            "minimum_age": "16 Years"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965470", 
            "org_study_id": "CDC-CGH-6475"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combination Prevention", 
                "intervention_name": "Combination Prevention", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Enhanced Care", 
                "intervention_name": "Enhanced Care", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Multiple", 
                    "country": "Botswana"
                }, 
                "name": "Botswana communities and Botswana Ministry of Health clinics"
            }
        }, 
        "location_countries": {
            "country": "Botswana"
        }, 
        "number_of_arms": "2", 
        "official_title": "Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #2): Estimating Risks and Benefits for HIV-Infected Adults of Early Initiation of Antiretroviral Therapy at CD4>350 Cells/\u00b5l if Viral Load is \u226510,000 Copies/mL: A Cluster-Randomized Trial -Intervention Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana", 
        "overall_official": [
            {
                "affiliation": "Centers for Disease Control and Prevention", 
                "last_name": "Janet S Moore, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Centers for Disease Control and Prevention", 
                "last_name": "William C Levine, MD, MSc", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Harvard School of Public Health", 
                "last_name": "Myron Essex, DVM, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Harvard School of Public Health", 
                "last_name": "Victor DeGruttola, SM, ScD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Botswana Ministry of Health", 
                "last_name": "Refeletswe Lebelonyane, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Botswana Ministry of Health", 
                "last_name": "Shenaaz El Halabi, MPH", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Population-level cumulative HIV incidence will be measured in a cohort of HIV-negative persons identified from a 20% sample of eligible households in the 30 study communities followed annually.", 
            "measure": "Population-level, cumulative HIV incidence", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Population-level uptake of each intervention will be measured in an annual survey of the 20% sample of eligible households in the 30 study communities and through analysis of routine program monitoring data.", 
                "measure": "Population-level uptake of HIV testing and counseling (HTC), ART, male circumcision, and PMTCT services", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Cost per additional infection averted", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinical outcomes for initially ART-na\u00efve, HIV-infected adults, with CD4>350 cells/\u00b5L and WHO Stage I/II", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Safety of ART for combination prevention community residents who start ART due to a high viral load (VL\u226510,000 copies/ml) when baseline CD4 is >350 cells/\u00b5L and WHO Stage is I/II, or who continue ART following PMTCT (Option B+)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Centers for Disease Control and Prevention", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Botswana-Harvard AIDS Institute Partnership", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Botswana Ministry of Health", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Harvard School of Public Health", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tebelopele", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Centers for Disease Control and Prevention", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}